Michael P. Phalen Sells 15,500 Shares of Boston Scientific Corporation (BSX) Stock

Boston Scientific Corporation (NYSE:BSX) EVP Michael P. Phalen sold 15,500 shares of the stock in a transaction dated Monday, July 31st. The stock was sold at an average price of $27.13, for a total transaction of $420,515.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Michael P. Phalen also recently made the following trade(s):

  • On Thursday, June 29th, Michael P. Phalen sold 15,500 shares of Boston Scientific Corporation stock. The shares were sold at an average price of $28.02, for a total transaction of $434,310.00.
  • On Tuesday, May 30th, Michael P. Phalen sold 15,500 shares of Boston Scientific Corporation stock. The shares were sold at an average price of $27.25, for a total transaction of $422,375.00.

Shares of Boston Scientific Corporation (NYSE BSX) traded up 0.94% during trading on Friday, reaching $26.89. 5,850,175 shares of the company traded hands. The stock has a market cap of $36.90 billion, a P/E ratio of 48.10 and a beta of 1.09. The stock’s 50 day moving average price is $27.16 and its 200-day moving average price is $26.15. Boston Scientific Corporation has a 12 month low of $19.67 and a 12 month high of $28.51.

Boston Scientific Corporation (NYSE:BSX) last released its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $0.32 EPS for the quarter, beating the consensus estimate of $0.31 by $0.01. The company had revenue of $2.26 billion during the quarter, compared to the consensus estimate of $2.21 billion. Boston Scientific Corporation had a return on equity of 23.62% and a net margin of 9.04%. The firm’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.27 EPS. On average, equities research analysts expect that Boston Scientific Corporation will post $1.26 EPS for the current fiscal year.

WARNING: This piece was first reported by BNB Daily and is owned by of BNB Daily. If you are reading this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.baseball-news-blog.com/2017/08/19/insider-selling-boston-scientific-corporation-bsx-evp-sells-15500-shares-of-stock-updated-updated.html.

Large investors have recently bought and sold shares of the stock. Toronto Dominion Bank boosted its stake in Boston Scientific Corporation by 56.7% in the first quarter. Toronto Dominion Bank now owns 367,924 shares of the medical equipment provider’s stock worth $9,150,000 after buying an additional 133,121 shares during the period. Koch Industries Inc. acquired a new stake in Boston Scientific Corporation during the first quarter worth $307,000. Bellevue Group AG boosted its stake in Boston Scientific Corporation by 4.0% in the first quarter. Bellevue Group AG now owns 572,000 shares of the medical equipment provider’s stock worth $14,226,000 after buying an additional 22,000 shares during the period. Private Wealth Partners LLC boosted its stake in Boston Scientific Corporation by 0.4% in the second quarter. Private Wealth Partners LLC now owns 208,051 shares of the medical equipment provider’s stock worth $5,767,000 after buying an additional 785 shares during the period. Finally, Principal Financial Group Inc. boosted its stake in Boston Scientific Corporation by 1.7% in the first quarter. Principal Financial Group Inc. now owns 1,983,944 shares of the medical equipment provider’s stock worth $49,340,000 after buying an additional 33,763 shares during the period. Institutional investors and hedge funds own 91.62% of the company’s stock.

Several research firms have commented on BSX. Zacks Investment Research cut shares of Boston Scientific Corporation from a “buy” rating to a “hold” rating in a research note on Thursday, June 29th. BMO Capital Markets reissued a “buy” rating and set a $30.00 target price on shares of Boston Scientific Corporation in a research note on Wednesday, June 21st. Royal Bank Of Canada reissued an “ourperform” rating and set a $29.00 target price (down previously from $31.00) on shares of Boston Scientific Corporation in a research note on Friday, June 9th. Needham & Company LLC raised their target price on shares of Boston Scientific Corporation from $30.00 to $32.00 and gave the company a “buy” rating in a research note on Thursday, June 22nd. Finally, BidaskClub raised shares of Boston Scientific Corporation from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 10th. Six research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Boston Scientific Corporation has an average rating of “Buy” and an average price target of $30.06.

About Boston Scientific Corporation

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Insider Buying and Selling by Quarter for Boston Scientific Corporation (NYSE:BSX)

Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply